NCT04042753View on ClinicalTrials.gov

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
PituitaryPituitary TumorPituitary CarcinomaPituitary Cancer
Interventions
DRUG

Ipilimumab

Ipilimumab 3 mg/kg every 3 weeks,

DRUG

Nivolumab

Nivolumab 1 mg/kg every 3 weeks for 4 cycles

DRUG

Nivolumab

Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first

Trial Locations (8)

10021

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack

90048

Cedars-Sinai Medical Center, Los Angeles

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04042753 - Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | Biotech Hunter | Biotech Hunter